MCID: HYP011
MIFTS: 42

Hyperlipoproteinemia Type Iii malady

Categories: Metabolic diseases, Genetic diseases, Endocrine diseases, Rare diseases

Aliases & Classifications for Hyperlipoproteinemia Type Iii

Aliases & Descriptions for Hyperlipoproteinemia Type Iii:

Name: Hyperlipoproteinemia Type Iii 12 52 42 14 69
Familial Hypercholesterolaemia with Hyperlipaemia 12
Familial Type 3 Hyperlipoproteinemia 12
Familial Hyperlipoproteinemia Type 3 29
Carbohydrate Induced Hyperlipemia 12
Remnant Hyperlipidemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3145
MeSH 42 D006952
NCIt 47 C34710
SNOMED-CT 64 398796005 42569002
UMLS 69 C0020479

Summaries for Hyperlipoproteinemia Type Iii

MalaCards based summary : Hyperlipoproteinemia Type Iii, also known as familial hypercholesterolaemia with hyperlipaemia, is related to hyperlipidemia type 3 and hyperchylomicronemia, late-onset. An important gene associated with Hyperlipoproteinemia Type Iii is APOE (Apolipoprotein E), and among its related pathways/superpathways are Metabolism and Metabolism of water-soluble vitamins and cofactors. The drugs Colesevelam Hydrochloride and Hypolipidemic Agents have been mentioned in the context of this disorder. Related phenotypes are Decreased free cholesterol and Increased LDL uptake

Related Diseases for Hyperlipoproteinemia Type Iii

Diseases in the Hyperlipoproteinemia Type Iv family:

Hyperlipoproteinemia, Type 1d Hyperlipoproteinemia, Type Ib
Hyperlipoproteinemia Type Iii

Diseases related to Hyperlipoproteinemia Type Iii via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 62)
id Related Disease Score Top Affiliating Genes
1 hyperlipidemia type 3 11.2
2 hyperchylomicronemia, late-onset 11.1
3 hyperlipoproteinemia type iv 11.1
4 cardiovascular disease risk factor ) 10.9
5 zap-70 deficiency 10.3 APOB APOE
6 alport syndrome and thin basement membrane nephropathy 10.3 APOE LPL
7 polycystic kidney disease, infantile severe, with tuberous sclerosis 10.2 LIPC LPL
8 keratoconus 4 10.2 APOB APOE LDLR
9 hypercholesterolemia, due to ligand-defective apo b 10.2 APOB APOE LDLR
10 cetp-related hyperalphalipoproteinemia 10.2 APOB APOE
11 myxofibrosarcoma 10.1 APOE LPL
12 c1s deficiency 10.1 APOA5 APOE LPL
13 abducens nerve neoplasm 10.1 APOA5 LIPC LPL
14 familial progressive cardiac conduction defect 10.1 APOA1 APOE
15 alzheimer disease 19, late onset 10.1 APOB APOE LDLR LPA
16 exudative vitreoretinopathy 2, x-linked 10.1 APOB COG2
17 asphyxia neonatorum 10.1 APOE LDLR LPA LPL
18 pars planitis 10.1 APOA1 APOE
19 primary pigmented nodular adrenocortical disease 10.0 APOA1 APOB APOE
20 dyserythropoietic anemia, congenital, type ii 10.0 APOA1 APOE LPA
21 congenital chloride diarrhea 10.0 APOA1 APOB LPA
22 anaplastic ganglioglioma 10.0 APOA1 LPA
23 albinism, oculocutaneous, type v 10.0 APOA1 APOB APOE LPA
24 pontocerebellar hypoplasia, type 10 9.9 APOE HMGCR LDLR
25 joint disorders 9.9 APOA1 APOB APOE LPL
26 camptodactyly-arthropathy-coxa vara-pericarditis syndrome 9.9 APOB APOE CETP LIPC
27 cervix small cell carcinoma 9.9 APOA1 APOB APOE LDLR
28 hyperchlorhidrosis, isolated 9.9 APOA1 APOE LIPC LPL
29 gait apraxia 9.9 APOA1 APOB APOE CETP
30 posterior uveal melanoma 9.9 APOA1 APOB COG2
31 craniodiaphyseal dysplasia 9.9 APOA1 APOB
32 dentinogenesis imperfecta type 2 9.9 APOB APOE HMGCR LDLR
33 body dysmorphic disorder 9.9 APOA1 APOB COG2
34 fibrosarcoma of bone 9.9 APOB HMGCR LDLR LPA
35 bird fancier's lung 9.8 APOA1 APOB APOE LPA LPL
36 transient retinal arterial occlusion 9.8 APOA1 APOB HMGCR
37 neuropathy, hereditary sensory and autonomic, type ia 9.8 APOA1 APOB APOE CETP LPA
38 mannosidosis, beta 9.8 APOA1 APOB APOE CETP LPL
39 optic nerve neoplasm 9.8 APOA1 APOB APOE COG2 LPA
40 spinocerebellar ataxia 20 9.7 APOA1 APOB HMGCR LPA
41 chondrocalcinosis with early-onset osteoarthritis 9.7 APOA1 APOB APOE CETP LPA LPL
42 diabetes mellitus, insulin-dependent, 20 9.7 APOA1 APOB COG2 LPA LPL
43 budd-chiari syndrome 9.7 APOB APOE COG2 HMGCR LPA
44 severe intellectual disability-progressive postnatal microcephaly- midline stereotypic hand movements syndrome 9.6 APOB APOE HMGCR LDLR LIPC LPL
45 von willebrand disease, platelet-type 9.6 APOA1 APOB APOE CETP LDLR LPA
46 cataract 5, multiple types 9.5 APOA1 APOB APOE CETP LDLR LIPC
47 stone in bladder diverticulum 9.5 APOA1 APOB APOE CETP COG2 LDLR
48 myelophthisic anemia 9.4 APOA1 APOB APOE COG2 HMGCR LPA
49 hypertriglyceridemia 9.4 APOA1 APOB APOE CETP LDLR LIPC
50 pericarditis 9.4 APOA1 APOB APOE HMGCR LDLR LPA

Graphical network of the top 20 diseases related to Hyperlipoproteinemia Type Iii:



Diseases related to Hyperlipoproteinemia Type Iii

Symptoms & Phenotypes for Hyperlipoproteinemia Type Iii

GenomeRNAi Phenotypes related to Hyperlipoproteinemia Type Iii according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 9.65 APOA1 APOA5 APOB APOE CETP HMGCR
2 Increased LDL uptake GR00340-A-1 8.92 APOA1 APOE LDLR LPL

MGI Mouse Phenotypes related to Hyperlipoproteinemia Type Iii:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.65 APOA1 APOA5 APOB APOE COG2 HMGCR
2 liver/biliary system MP:0005370 9.1 APOA1 APOB APOE HMGCR LDLR LPL

Drugs & Therapeutics for Hyperlipoproteinemia Type Iii

Drugs for Hyperlipoproteinemia Type Iii (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 25)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Colesevelam Hydrochloride Phase 4
2 Hypolipidemic Agents Phase 4,Phase 3
3 Anticholesteremic Agents Phase 4,Phase 3
4 Lipid Regulating Agents Phase 4,Phase 3
5 Antimetabolites Phase 4,Phase 3
6
Ezetimibe Approved Phase 3 163222-33-1 150311
7
Pravastatin Approved Phase 3 81093-37-0 54687
8
Simvastatin Approved Phase 3 79902-63-9 54454
9
Fluvastatin Approved Phase 3 93957-54-1 1548972
10
Pitavastatin Approved Phase 3 147511-69-1, 147526-32-7 6366718 5282452
11
Fosamprenavir Approved Phase 3 226700-79-4 131536
12
Fenofibrate Approved Phase 3 49562-28-9 3339
13 Calcium, Dietary Phase 3
14 Atorvastatin Calcium Phase 3 134523-03-8
15 Rosuvastatin Calcium Phase 3 147098-20-2
16 Pharmaceutical Solutions Phase 3
17 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3,Phase 2
18 Immunoglobulins Phase 3,Phase 2
19 Antibodies, Monoclonal Phase 3,Phase 2
20 Antibodies Phase 3,Phase 2
21
Torcetrapib Phase 3 262352-17-0 159325
22
Cobalt Phase 2 7440-48-4 104729
23 Trace Elements Phase 2
24 Micronutrients Phase 2
25 Phytosterol Nutraceutical

Interventional clinical trials:

(show all 20)
id Name Status NCT ID Phase
1 A Study of the Safety and Efficacy of Patients With Familial Hypercholesterolaemia Taking Colesevelam as add-on Therapy to Their Existing Medication Completed NCT00655265 Phase 4
2 Type III Dysbetalipoproteinemia Completed NCT00214604 Phase 3
3 A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH) Completed NCT00730236 Phase 3
4 Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia Completed NCT00943306 Phase 3
5 A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384) Completed NCT02460159 Phase 3
6 The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome Completed NCT02211209 Phase 3
7 A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome Completed NCT01514461 Phase 3
8 Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN) Completed NCT02107898 Phase 3
9 A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia Completed NCT01968980 Phase 3
10 A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833) Active, not recruiting NCT02748057 Phase 3
11 Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder. Terminated NCT00145431 Phase 3
12 Efficacy and Safety Study of Eprotirome in HeFH Patients Who Are on Optimal Standard of Care Terminated NCT01410383 Phase 3
13 Study to Evaluate the Effects of MBX-8025 in Patients With HoFH Completed NCT02472535 Phase 2
14 Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1) Recruiting NCT02722408 Phase 2
15 Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C) Active, not recruiting NCT02597127 Phase 2
16 An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol Not yet recruiting NCT03060577 Phase 2
17 DARK STUDY "DysbetalipoproteinemiA and atheRoma Risk" Unknown status NCT01760265
18 Effect of Weight Loss on Cholesterol Metabolism in Hereditary Hypercholesterolemias and Overweight or Obesity. Completed NCT01995149
19 Evaluation of Lipoproteins Recruiting NCT00001168
20 The Spanish Familial Hypercholesterolaemia Cohort Study Recruiting NCT02693548

Search NIH Clinical Center for Hyperlipoproteinemia Type Iii

Cochrane evidence based reviews: hyperlipoproteinemia type iii

Genetic Tests for Hyperlipoproteinemia Type Iii

Genetic tests related to Hyperlipoproteinemia Type Iii:

id Genetic test Affiliating Genes
1 Familial Type 3 Hyperlipoproteinemia 29

Anatomical Context for Hyperlipoproteinemia Type Iii

Publications for Hyperlipoproteinemia Type Iii

Articles related to Hyperlipoproteinemia Type Iii:

id Title Authors Year
1
[Apolipoprotein E phenotyping--useful in the study of hyperlipoproteinemia type III]. ( 8480294 )
1993
2
Normolipemic dysbetalipoproteinemia and hyperlipoproteinemia type III in subjects homozygous for a rare genetic apolipoprotein E variant (apoE1). ( 1973700 )
1990
3
Serum and interstitial fluid apolipoprotein E levels in the healthy and in hyperlipoproteinemia type III as studied by radioimmunoassay. ( 4042371 )
1985
4
Apolipoprotein E (role in lipoprotein metabolism and pathophysiology of hyperlipoproteinemia type III). ( 6283616 )
1982
5
Polymorphism of apolipoprotein E. II. Genetics of hyperlipoproteinemia type III. ( 215360 )
1979
6
Polymorphism of apolipoprotein E. I. Methodological aspects and diagnosis of hyperlipoproteinemia type III without ultracentrifugation. ( 215358 )
1978
7
Familial hyperlipoproteinemia type III: deficiency of a specific apolipoprotein (apo E-III) in the very-low-density lipoproteins. ( 169165 )
1975

Variations for Hyperlipoproteinemia Type Iii

ClinVar genetic disease variations for Hyperlipoproteinemia Type Iii:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 APOE NM_000041.2(APOE): c.526C> T (p.Arg176Cys) single nucleotide variant drug response rs7412 GRCh37 Chromosome 19, 45412079: 45412079
2 APOE NM_000041.3(APOE): c.460C> A (p.Arg154Ser) single nucleotide variant Pathogenic rs121918393 GRCh37 Chromosome 19, 45412013: 45412013
3 APOE NM_000041.3(APOE): c.487C> T (p.Arg163Cys) single nucleotide variant Pathogenic rs769455 GRCh37 Chromosome 19, 45412040: 45412040
4 APOE NM_000041.3(APOE): c.237-2A> G single nucleotide variant Pathogenic rs397514253 GRCh37 Chromosome 19, 45411788: 45411788
5 APOE NM_000041.3(APOE) duplication Pathogenic rs397514254 GRCh37 Chromosome 19, 45411968: 45411988
6 APOE NM_000041.3(APOE): c.490A> G (p.Lys164Glu) single nucleotide variant Pathogenic rs121918394 GRCh37 Chromosome 19, 45412043: 45412043
7 APOE NM_000041.3(APOE): c.490A> C (p.Lys164Gln) single nucleotide variant Pathogenic rs121918394 GRCh37 Chromosome 19, 45412043: 45412043
8 APOE APOE, 1-BP DEL, 2919G deletion Pathogenic
9 APOE NM_000041.3(APOE): c.683G> A (p.Trp228Ter) single nucleotide variant Pathogenic rs121918396 GRCh37 Chromosome 19, 45412236: 45412236
10 APOE NM_000041.3(APOE): c.488G> A (p.Arg163His) single nucleotide variant Pathogenic rs121918397 GRCh37 Chromosome 19, 45412041: 45412041

Expression for Hyperlipoproteinemia Type Iii

Search GEO for disease gene expression data for Hyperlipoproteinemia Type Iii.

Pathways for Hyperlipoproteinemia Type Iii

Pathways related to Hyperlipoproteinemia Type Iii according to GeneCards Suite gene sharing:

(show all 14)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.63 APOA1 APOA5 APOB APOE CETP HMGCR
2
Show member pathways
12.33 APOA1 APOB APOE LDLR LPL
3
Show member pathways
12.14 APOA1 APOA5 APOB APOE CETP LDLR
4
Show member pathways
12 APOA1 APOB APOE LDLR
5
Show member pathways
11.88 APOA1 APOB APOE LDLR LPL
6 11.75 APOA1 APOA5 APOE
7
Show member pathways
11.65 APOA1 APOB APOE
8 11.47 HMGCR LDLR LPL
9 11.44 APOA1 APOA5 LPL
10
Show member pathways
11.11 APOA1 APOA5 APOB APOE CETP HMGCR
11 11.08 APOE LDLR
12 10.94 APOA1 APOA5
13 10.89 APOA1 APOB
14 10.77 HMGCR LDLR

GO Terms for Hyperlipoproteinemia Type Iii

Cellular components related to Hyperlipoproteinemia Type Iii according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 9.83 APOA1 APOA5 APOB APOE LIPC
2 early endosome GO:0005769 9.78 APOA1 APOB APOE LDLR
3 blood microparticle GO:0072562 9.69 APOA1 APOA5 APOE
4 high-density lipoprotein particle GO:0034364 9.65 APOA1 APOA5 APOE CETP LIPC
5 clathrin-coated endocytic vesicle membrane GO:0030669 9.63 APOB APOE LDLR
6 endocytic vesicle lumen GO:0071682 9.58 APOA1 APOB APOE
7 very-low-density lipoprotein particle GO:0034361 9.55 APOA1 APOA5 APOB APOE LPL
8 intermediate-density lipoprotein particle GO:0034363 9.5 APOA1 APOB APOE
9 low-density lipoprotein particle GO:0034362 9.35 APOA1 APOA5 APOB APOE LDLR
10 chylomicron GO:0042627 9.02 APOA1 APOA5 APOB APOE LPL
11 extracellular region GO:0005576 10.1 APOA1 APOA5 APOB APOE CETP LIPC
12 extracellular space GO:0005615 10.02 APOA1 APOA5 APOB APOE CETP LDLR

Biological processes related to Hyperlipoproteinemia Type Iii according to GeneCards Suite gene sharing:

(show all 50)
id Name GO ID Score Top Affiliating Genes
1 post-translational protein modification GO:0043687 9.99 APOA1 APOA5 APOB APOE
2 cellular protein metabolic process GO:0044267 9.96 APOA1 APOA5 APOB APOE
3 lipid transport GO:0006869 9.95 APOA1 APOA5 APOB APOE CETP LDLR
4 retinoid metabolic process GO:0001523 9.91 APOA1 APOB APOE LPL
5 triglyceride metabolic process GO:0006641 9.88 APOA5 APOE CETP LPL
6 cholesterol transport GO:0030301 9.88 APOA1 APOB CETP LDLR LIPC
7 lipid catabolic process GO:0016042 9.87 APOB LIPC LPL
8 cholesterol metabolic process GO:0008203 9.87 APOA1 APOB APOE CETP HMGCR LDLR
9 regulation of lipid metabolic process GO:0019216 9.86 APOA1 APOA5 HMGCR
10 cholesterol efflux GO:0033344 9.86 APOA1 APOA5 APOB APOE
11 high-density lipoprotein particle remodeling GO:0034375 9.85 APOA1 APOE CETP LIPC
12 chylomicron remodeling GO:0034371 9.83 APOA1 APOB APOE LPL
13 reverse cholesterol transport GO:0043691 9.83 APOA1 APOA5 APOE CETP LIPC
14 phospholipid transport GO:0015914 9.81 APOA1 CETP LDLR
15 cholesterol biosynthetic process GO:0006695 9.81 APOA1 APOA5 HMGCR
16 chylomicron remnant clearance GO:0034382 9.81 APOB APOE LDLR LIPC
17 high-density lipoprotein particle assembly GO:0034380 9.8 APOA1 APOA5 APOE
18 very-low-density lipoprotein particle remodeling GO:0034372 9.8 APOE CETP LIPC LPL
19 phospholipid efflux GO:0033700 9.79 APOA1 APOA5 APOE
20 lipoprotein biosynthetic process GO:0042158 9.78 APOA1 APOB APOE
21 chylomicron assembly GO:0034378 9.77 APOA1 APOB APOE
22 positive regulation of cholesterol esterification GO:0010873 9.77 APOA1 APOA5 APOE
23 low-density lipoprotein particle remodeling GO:0034374 9.77 APOB APOE CETP LIPC LPA
24 neuron projection regeneration GO:0031102 9.76 APOA1 APOA5 APOE
25 lipoprotein catabolic process GO:0042159 9.74 APOB APOE LDLR
26 triglyceride homeostasis GO:0070328 9.73 APOA1 APOA5 APOE CETP LIPC LPL
27 regulation of cholesterol biosynthetic process GO:0045540 9.71 APOB HMGCR
28 lipid homeostasis GO:0055088 9.71 APOE CETP
29 low-density lipoprotein particle clearance GO:0034383 9.7 APOB LDLR
30 artery morphogenesis GO:0048844 9.7 APOB APOE
31 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.7 APOB LPL
32 phosphatidylcholine metabolic process GO:0046470 9.69 APOA5 CETP
33 positive regulation of fatty acid biosynthetic process GO:0045723 9.69 APOA1 APOA5
34 regulation of lipoprotein lipase activity GO:0051004 9.68 LIPC LPL
35 positive regulation of lipoprotein lipase activity GO:0051006 9.68 APOA1 APOA5
36 phospholipid homeostasis GO:0055091 9.68 APOA1 CETP
37 high-density lipoprotein particle clearance GO:0034384 9.67 APOA1 APOE
38 positive regulation of triglyceride catabolic process GO:0010898 9.67 APOA1 APOA5
39 positive regulation of cholesterol storage GO:0010886 9.67 APOB LPL
40 cholesterol import GO:0070508 9.66 APOA1 LDLR
41 very-low-density lipoprotein particle clearance GO:0034447 9.65 APOB APOE
42 regulation of Cdc42 protein signal transduction GO:0032489 9.65 APOA1 APOE
43 regulation of intestinal cholesterol absorption GO:0030300 9.65 APOA1 APOA5
44 triglyceride catabolic process GO:0019433 9.63 APOA1 APOA5 APOB APOE LIPC LPL
45 cholesterol homeostasis GO:0042632 9.56 APOA1 APOA5 APOB APOE CETP LDLR
46 lipoprotein metabolic process GO:0042157 9.23 APOA1 APOA5 APOB APOE CETP LDLR
47 transport GO:0006810 10.24 APOA1 APOA5 APOB APOE CETP COG2
48 lipid metabolic process GO:0006629 10.11 APOA1 APOB APOE CETP HMGCR LDLR
49 receptor-mediated endocytosis GO:0006898 10.03 APOA1 APOB APOE CETP LDLR
50 steroid metabolic process GO:0008202 10.01 APOA1 APOB APOE CETP HMGCR LDLR

Molecular functions related to Hyperlipoproteinemia Type Iii according to GeneCards Suite gene sharing:

(show all 18)
id Name GO ID Score Top Affiliating Genes
1 lipid binding GO:0008289 9.88 APOA1 APOA5 APOB APOE CETP
2 phospholipid binding GO:0005543 9.73 APOA1 APOA5 APOB APOE
3 phosphatidylcholine binding GO:0031210 9.63 APOA1 APOA5 CETP
4 cholesterol binding GO:0015485 9.62 APOA1 APOA5 APOE CETP
5 beta-amyloid binding GO:0001540 9.58 APOA1 APOE
6 low-density lipoprotein particle receptor binding GO:0050750 9.58 APOA5 APOB APOE
7 triglyceride lipase activity GO:0004806 9.57 LIPC LPL
8 phospholipid transporter activity GO:0005548 9.56 APOA1 CETP
9 low-density lipoprotein particle binding GO:0030169 9.55 LDLR LIPC
10 phospholipase activity GO:0004620 9.54 LIPC LPL
11 apolipoprotein binding GO:0034185 9.54 LIPC LPA LPL
12 lipase binding GO:0035473 9.52 APOA5 APOB
13 lipoprotein particle binding GO:0071813 9.51 APOA1 APOE
14 triglyceride binding GO:0017129 9.49 CETP LPL
15 lipid transporter activity GO:0005319 9.46 APOA1 APOB APOE CETP
16 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.43 APOA1 APOA5 APOE
17 heparin binding GO:0008201 9.43 APOA5 APOB APOE LIPC LPA LPL
18 cholesterol transporter activity GO:0017127 9.02 APOA1 APOA5 APOB APOE CETP

Sources for Hyperlipoproteinemia Type Iii

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....